Results 291 to 300 of about 159,806 (339)

Polyglycolic Acid Sheet Application to Refractory Delayed Bleeding After Rectal Endoscopic Submucosal Dissection: A Case Report

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT A man in his 50s underwent endoscopic submucosal dissection (ESD) for a rectal tumor measuring 28 mm. He was not taking any antithrombotic medication. On the third, 11th, 18th, and 24th days after the procedure, bleeding was observed from different areas of the ulcer bed margin and was managed with hemostatic forceps.
Yoshiko Nakano, Katsutoshi Kuriyama, Yasuhiro Watanabe, Shin'ichi Miyamoto   +3 more
wiley   +1 more source

Safety Profile of Low‐Power Pure‐Cut Hot Snare Polypectomy for 10–14 mm Nonpedunculated Colorectal Neoplasms

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Objectives The reported rate of delayed bleeding (DB) after hot snare polypectomy (HSP) for 10–19‐mm polyps is 2.1%–2.8%, which is non‐negligible. We hypothesized that a low‐power pure‐cut current (LPPC) yields a lower risk of DB than a coagulation current, and we evaluated the safety of LPPC HSP for colorectal polyps.
Kazunori Takada, Hidenori Kimura, Kinichi Hotta, Kenichiro Imai, Sayo Ito, Yoshihiro Kishida, Noboru Kawata, Masao Yoshida, Yoichi Yamamoto, Tatsunori Minamide, Hirotoshi Ishiwatari, Junya Sato, Hiroyuki Matsubayashi, Hiroyuki Ono   +13 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium

Circulation, 2023
Antiplatelet therapy is the mainstay of pharmacologic treatment to prevent thrombotic or ischemic events in patients with coronary artery disease treated with percutaneous coronary intervention and those treated medically for an acute coronary syndrome ...
D. Capodanno, R. Mehran, M. Krucoff, U. Baber, Deepak L. Bhatt, P. Capranzano, J. Collet, T. Cuisset, G. De Luca, L. De Luca, A. Farb, Francesco Franchi, C. Gibson, J. Hahn, M. Hong, S. James, A. Kastrati, T. Kimura, P. Lemos, R. Lopes, Adrian Magee, R. Matsumura, S. Mochizuki, M. O’Donoghue, N. Pereira, S. Rao, F. Rollini, Y. Shirai, D. Sibbing, P. Smits, P. Steg, R. Storey, Jurrien ten Berg, M. Valgimigli, P. Vranckx, Hirotoshi Watanabe, S. Windecker, P. Serruys, R. Yeh, M. Morice, D. Angiolillo   +40 more
semanticscholar   +1 more source

Personalised antiplatelet therapies for coronary artery disease: what the future holds.

European Heart Journal, 2023
Coronary artery disease (CAD) is one of the leading causes of death globally, and antiplatelet therapy is crucial for both its prevention and treatment.
D. Capodanno, D. Angiolillo
semanticscholar   +1 more source

Antiplatelet drugs

European Journal of Clinical Investigation, 1994
Abstract.The evidence in support of the safety and efficacy of aspirin in the secondary prevention of platelet dependent vascular occlusion is compelling. The utility of this drug has stalled the development of potential competitors, such as thromboxane antagonists.
G A, Fitzgerald, E A, Meagher
openaire   +2 more sources

Clinical pharmacology of antiplatelet drugs

Expert Review of Clinical Pharmacology, 2022
Introduction Platelets play a key role in arterial thrombosis and antiplatelet therapy is pivotal in the treatment of cardiovascular disease. Current antiplatelet drugs target different pathways of platelet activation and show specific pharmacodynamic ...
Georg Gelbenegger, B. Jilma
semanticscholar   +1 more source

Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry.

European Heart Journal, 2021
AIMS The role of antiplatelet therapy in patients with spontaneous coronary artery dissection (SCAD) undergoing initial conservative management is still a matter of debate, with theoretical arguments in favour and against its use.
E. Cerrato, F. Giacobbe, G. Quadri, F. Macaya, M. Bianco, R. Mori, C. Biolè, A. Boi, L. Bettari, C. Rolfo, F. Ferrari, G. Annibali, M. Scappaticci, M. Pavani, U. Barbero, D. Buccheri, C. Cavallino, P. Lombardi, C. Bernelli, F. D’Ascenzo, V. Infantino, A. Gambino, S. Cinconze, A. Rognoni, L. Montagna, I. Porto, G. Musumeci, J. Escaned, F. Varbella   +28 more
semanticscholar   +1 more source

Antiplatelet drugs

Medical Journal of Australia, 1999
Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and other serious vascular events in patients with a history of previous vascular events or known risk factors for cardiovascular disease. Aspirin reduces the risk of serious vascular events in patients at high risk of such an event by about a quarter and is ...
R I, Baker, G J, Hankey
openaire   +3 more sources

Antiplatelet agents

Hematology, 2009
Abstract The introduction of aspirin as an anti-thrombotic agent some 50 years ago has changed the therapeutic approach in cardiovascular medicine. Since platelets play a key role in the development of arterial thrombosis, antiplatelet drugs serve as a cornerstone in the prevention and the treatment of these conditions.
David, Varon, Galia, Spectre
openaire   +2 more sources

Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.

Journal of the American Medical Association (JAMA), 2021
Importance Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in the United States with an annual incidence of approximately 1 million.
Hassan Kamran, H. Jneid, Waleed T. Kayani, S. Virani, G. Levine, Vijay Nambi, Umair Khalid   +6 more
semanticscholar   +1 more source